gemcitabine has been researched along with n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bridgewater, J; Cascinu, S; Childs, BH; Dueland, S; Garosi, VL; Giurescu, M; Haas, M; Jassem, J; Martens, UM; Melichar, B; Michl, P; Peeters, M; Rajagopalan, P; Riess, H; Ross, P; Roth, K; Saramak, P; Schmiegel, W; Schulz, A; Seidel, H; Teufel, M; Van Brummelen, D; Van Laethem, JL; Weekes, C; Zaniboni, A | 1 |
1 trial(s) available for gemcitabine and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diphenylamine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome | 2017 |
1 other study(ies) available for gemcitabine and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |